Overview: NGS Retinitis Pigmentosa Sequencing TestIntroduction: The NGS Retinitis Pigmentosa Sequencing Test sequences genes to diagnose retinitis pigmentosa, causing night blindness or vision loss. Following 2023 AAO guidelines, it uses PCR for high specificity, supporting vision screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected retinitis pigmentosa (RP).
Other Names: RP Assay, RHO/USH2A Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: RP sequencing began in the 1990s with retinal dystrophy research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose retinitis pigmentosa, guides treatment, and evaluates patients with night blindness or vision loss.
Test Parameters: 1. Retinitis Pigmentosa Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of night blindness, vision loss, or RP symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document night blindness, peripheral vision loss, or family history of RP. Include current medications, especially vision-related treatments.
Consent: Written consent required, detailing the tests purpose, RP implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze RP genes (e.g., RHO, USH2A). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for RP diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm RP, guiding vitamin A therapy or genetic counseling. Negative results may require broader retinal panels.
Specialist Consultation: Consult an ophthalmologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: ERG, visual field testing, or retinal imaging to confirm RP diagnosis.
Test Limitations: Not all RP cases are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: AAO RP Guidelines, 2023; Ophthalmology, Hartong DT, 2022.
